Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Lizasoaín, et al.
Gastroenterología y Hepatología (English Edition) (2019) Vol. 42, Iss. 8, pp. 465-475
Closed Access | Times Cited: 9

Showing 9 citing articles:

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan
Daisuke Nakamoto, Yi Piao, Hajime Mizutani, et al.
Journal of Pharmaceutical Health Care and Sciences (2025) Vol. 11, Iss. 1
Open Access
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study
Takeya Tsutsumi, Hiroshi Yotsuyanagi
Kanzo (2024) Vol. 65, Iss. 8, pp. 368-390
Open Access | Times Cited: 2
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
Po‐Yao Hsu, Yu‐Ju Wei, Jia‐Jung Lee, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 1, pp. 186-196
Open Access | Times Cited: 15
Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study
Alessandra Mangia, Francesco Scaglione, Pierluigi Toniutto, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 13, pp. 7144-7144
Open Access | Times Cited: 14
Anti-epileptic drugs and hepatitis C therapy: Real-world experience
Cristina Marcos‐Fosch, Joaquín Cabezas, Javier Crespo, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 984-985
Closed Access | Times Cited: 10
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study
Michael P. Curry, Steven L. Flamm, Scott Milligan, et al.
Journal of Managed Care & Specialty Pharmacy (2021) Vol. 27, Iss. 9, pp. 1239-1248
Open Access | Times Cited: 6
Patients’ preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection
Ma Angustias Quesada Simón, O Rojo, Pablo Ryan
Revista Española de Sanidad Penitenciaria (2021) Vol. 23, Iss. 2, pp. 67-75
Open Access | Times Cited: 3
Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Darrag, et al.
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1261-1268
Open Access
Resource utilization associated with the management of potential interactions between direct-acting antivirals for chronic hepatitis C treatment and cardiovascular and central nervous system drugs
Esther Molina, Marta Torrens, Javier Ampuero, et al.
Economía de la Salud (2022) Vol. 17, pp. 108-119
Open Access
Page 1

Scroll to top